CSF2 and neuroblastoma: Dinutuximab used together with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin was licensed in March 2015 by the U.S. Food and Drug Administration (FDA) “for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line, multi-agent, multimodality therapy” (79).